Woman who died after getting AstraZeneca vaccine had ‘unusual symptoms’: report

0
12

[ad_1]

A 60-year-old Danish woman who received the AstraZeneca COVID-19 vaccine had “highly unusual symptoms” before dying of a blood clot, according to a report.

The woman had a low number of blood platelets and clots in small and large vessels, Reuters reported, citing the Danish Medicines Agency.

The agency cited a few similar cases reported in Norway and in the European Medicines Agency database of drug side effects, according to the news outlet.

“It was an unusual course of illness around the death that made the Danish Medicines Agency react,” it said in a statement Sunday night.

On Saturday, Norway said three people — all under age 50 — who had received the jab were being treated in a hospital for bleeding, blood clots and a low count of blood platelets, which health officials labeled “unusual symptoms.”

Denmark, Norway and Iceland said last week they would halt the introduction of the AstraZeneca shot.

AstraZeneca tried to quell safety concerns after blood clots emerged in some people who received their COVID-19 vaccine.
AstraZeneca tried to quell safety concerns after blood clots emerged in some people who received their COVID-19 vaccine.
Chris Jackson/Getty Images

European vaccination programs have been rocked by recent reports that recipients of the AstraZeneca inoculation have suffered blood clots.

The European Medicines Agency has said there is no indication that the cases were related to the vaccination, a view that was echoed by the World Health Organization on Friday.

AstraZeneca tried to quell safety concerns after blood clots emerged in some people, prompting about a dozen nations to stop using some or all of their doses.

The British drugmaker’s review of safety data from more than 17 million people who received the shot in the UK and the European Union found no evidence of a higher risk for pulmonary embolism or deep vein thrombosis, conditions associated with clots, it said in a Sunday statement.

There were also no signs of a higher risk for thrombocytopenia, or a low count of blood platelets, according to AstraZeneca.

[ad_2]

Source link